A multi-centre, double-blind, randomised controlled trial to evaluate the efficacy of 10 valent-pneumococcal-Protein D conjugate vaccine compared to quadrivalent (ACYW135) meningococcal conjugate vaccine in reducing respiratory exacerbations in children aged greater than or equal to 18 months with suppurative lung disease.
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Lung disorders; Respiratory tract disorders
- Focus Therapeutic Use
- Acronyms CHiRRP
- 16 Oct 2018 Status changed from recruiting to discontinued.
- 28 Nov 2013 New trial record